Read by QxMD icon Read

Neurodegenerative Disease Management

Volker Limmroth, Iason Bartzokis, Eckhard Bonmann, Patrick Kusel, Thomas Schreiner, Markus Schürks
Adherence to long-term treatment in chronic diseases such as multiple sclerosis is challenging. Many disease-modifying drugs (DMDs) for MS need to be injected. Injection devices may improve satisfaction with the injection procedure and boost adherence. Meeting patients' needs in handling and design of autoinjectors and other supporting elements may be key to successful therapy. The BETACONNECT™ system is a platform-based approach in DMD therapy. It combines autoinjector technology with digital tools to support patient self-management and facilitate communication between patients and healthcare providers...
October 3, 2018: Neurodegenerative Disease Management
Bruce D Trapp, Daniel Ontaneda
Dr Bruce Trapp and Dr Daniel Ontaneda speak to Laura Dormer, Commissioning Editor: Bruce D Trapp, PhD, is a Chair of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic (OH, USA) and Professor of Molecular Medicine at Case Western Reserve University (OH, USA). Dr Trapp received his PhD from Loyola University Stritch School of Medicine in Chicago (IL, USA). Dr Trapp's research investigates the cause of neurological disability in multiple sclerosis patients, cellular mechanism of brain repair in neurodegenerative diseases and the molecular biology of myelination in the central and peripheral nervous systems...
September 14, 2018: Neurodegenerative Disease Management
Danko Coric, Jenny A Nij Bijvank, Laurentius J van Rijn, Axel Petzold, Lisanne J Balk
In this review, a current overview is provided of how optical coherence tomography and infrared oculography can aid in assessing the visual system and CNS in multiple sclerosis (MS). Both afferent and efferent visual disorders are common in MS and visual complaints can have a tremendous impact on daily functioning. Optical coherence tomography and infrared oculography can detect and quantify visual disorders with high accuracy, but could also serve as quantitative markers for inflammation, neurodegeneration and network changes including cognitive decline in MS patients...
October 2018: Neurodegenerative Disease Management
Robert W Motl, Brian M Sandroff, Edward McAuley
AIM: This study examined the trajectory and pattern of naturally occurring change in perceived walking impairment over a 30-month period in relapsing-remitting multiple sclerosis (RRMS). PATIENTS & METHODS: Two hundred and sixty-nine persons with RRMS completed the 12-item Multiple Sclerosis Walking Scale (MSWS-12) every 6 months over a 30-month period. Data were analyzed using latent growth curve modeling and latent class growth curve modeling. RESULTS: Latent growth curve modeling demonstrated that a linear trajectory adequately described the group-level pattern of change in MSWS-12 scores over time...
October 2018: Neurodegenerative Disease Management
Yusuf A Rajabally
No abstract text is available yet for this article.
October 2018: Neurodegenerative Disease Management
Khashayar Dashtipour, Ali Tafreshi, Jessica Lee, Brianna Crawley
The prevalence of speech disorders among individuals with Parkinson's disease (PD) has been reported to be as high as 89%. Speech impairment in PD results from a combination of motor and nonmotor deficits. The production of speech depends upon the coordination of various motor activities: respiration, phonation, articulation, resonance and prosody. A speech disorder is defined as impairment in any of its inter-related components. Despite the high prevalence of speech disorders in PD, only 3-4% receive speech treatment...
October 2018: Neurodegenerative Disease Management
Andrew J Larner
AIM: To undertake a diagnostic test accuracy study of the Mini-Mental State Examination (MMSE) administered in primary care to patients who were subsequently referred to a cognitive disorders clinic in secondary care (n = 72). METHODS: MMSE scores from primary care were cross-classified with reference standard diagnoses made in secondary care, blind to MMSE score, in order to calculate standard measures of discrimination (including sensitivity and specificity, positive and negative predictive values)...
October 2018: Neurodegenerative Disease Management
Kerri S Rawson, Patricia Creel, Lizbeth Templin, Adam P Horin, Ryan P Duncan, Gammon M Earhart
AIM: In this pilot study, we evaluated the feasibility, safety and preliminary efficacy of a 6-week, community-based group intervention designed to reduce freezing of gait (FOG) for people with Parkinson's disease (PD). METHODS: Seven people with PD completed 'FOG Boot Camp' provided by the St. Louis Chapter of the American Parkinson Disease Association. We recorded attendance, participant's acceptance of the intervention and adverse events during classes. Pre and post-tests included measures of freezing, balance, motor severity, quality-of-life and gait speed...
October 2018: Neurodegenerative Disease Management
Annakaisa Haapasalo, Mikko Hiltunen
The international Kuopio Alzheimer Symposium was organized by the University of Eastern Finland in Kuopio, Finland on June 6-8, 2018 for the 8th time. Approximately 300 researchers in the fields of neuroscience and neurology from 12 different countries around the world gathered to Kuopio to hear and discuss about the latest insights into the mechanisms and comorbidities and novel approaches for diagnosis, prediction, prevention and therapies of Alzheimer's disease and other neurodegenerative diseases. The 2-day international program on June 7-8 included a keynote session, five oral scientific sessions and a poster session...
October 2018: Neurodegenerative Disease Management
Theresa Zesiewicz, Jason L Salemi, Susan Perlman, Kelly L Sullivan, Jessica D Shaw, Yangxin Huang, Charles Isaacs, Clifton Gooch, David R Lynch, Matthew B Klein
AIM: To evaluate the safety and clinical effects of EPI-743 in Friedreich's ataxia patients. EPI-743 is a compound that targets oxidoreductase enzymes essential for redox control of metabolism. METHODS: We conducted a multicenter trial that evaluated EPI-743 during a 6-month placebo-controlled phase, followed by an 18-month open-label phase. End points included low-contrast visual acuity and the Friedreich's Ataxia Rating Scale. RESULTS/CONCLUSION: EPI-743 was demonstrated to be safe and well tolerated...
August 2018: Neurodegenerative Disease Management
Mahmoud A Alomari, Hanan Khalil, Omar F Khabour, Robert Wood
AIM: The current study examined the relationship of handgrip, leg and arm neuromuscular performance with cardiovascular function in patients with Parkinson's disease (PD). MATERIALS & METHODS: Blood pressure, vascular measures and handgrip, shoulder and leg neuromuscular performance were obtained in PD persons and healthy controls. RESULTS: The data reveal that muscular and cardiovascular functions are altered (p < 0.05) in PD. Most importantly, regression indicates that altered central and peripheral cardiovascular function measures demonstrate a moderately strong relationship (p < 0...
August 2018: Neurodegenerative Disease Management
Josef Finsterer
No abstract text is available yet for this article.
August 2018: Neurodegenerative Disease Management
Rajesh R Tampi, Juan J Young, Deena J Tampi
No abstract text is available yet for this article.
August 2018: Neurodegenerative Disease Management
Philippe Huot
No abstract text is available yet for this article.
August 2018: Neurodegenerative Disease Management
Dana Mohammad, Courtney Ellis, Allison Rau, Myuri Ruthirakuhan, Krista L Lanctôt, Nathan Herrmann
Apathy is among the most prevalent neuropsychiatric symptom experienced in Parkinson's disease (PD) and can be assessed with a variety of scales. To identify which scale is most suitable for apathy assessment in PD, the psychometric properties of each scale and its sensitivity to change were analyzed. The methodological quality of the studies ranged from adequate to excellent. The Lille Apathy Rating Scale demonstrated consistently favorable psychometric properties and was used in two of four clinical trials found...
August 2018: Neurodegenerative Disease Management
Iracema Leroi, Keiko Kitagawa, Sabina Vatter, Taro Sugihara
Japan, as a 'super-aged' society, is at the forefront of the socioeconomic change resulting from the unprecedented demographic shift of aging societies, and is an exemplar for other countries. Within neurodegenerative disorders, a deeper understanding of the issues faced by aging societies, and their ramifications on the mental well being and cognitive health of older adults, is important. Japan's pioneering approaches in assistive technology and 'gerontotechnology' have the potential to enhance the field of dementia in terms of assessment, diagnosis and care...
August 2018: Neurodegenerative Disease Management
Christen F Kutz, Amy L Dix
Relapse management is a crucial component of multiple sclerosis care. Acute relapses are defined as new neurological symptoms or worsening of existing symptoms persisting for >24 h that are not attributable to heat, overexertion, or infection. The most commonly used treatment for multiple sclerosis relapse is a 3-5-day course of corticosteroids, primarily intravenous methylprednisolone with or without oral steroid taper. Repository corticotropin injection is also the US FDA-approved option for managing acute relapse, particularly in the patients with inadequate response, intolerability or allergy to corticosteroid treatment; poor venous access; or limited ability to receive home or clinic infusions...
August 2018: Neurodegenerative Disease Management
Stefan Wietek
AIM: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving Octagam® 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Data on patients with CIDP treated with Octagam were analyzed to assess its safety and tolerability. RESULTS: Of 2314 patients included in the studies, 58 patients (mean age: 64.6 years) received Octagam for CIDP, mean dose of which was 0...
August 2018: Neurodegenerative Disease Management
Robin Fackrell, Camille B Carroll, Donald G Grosset, Biju Mohamed, Prashanth Reddy, Miriam Parry, Kallol Ray Chaudhuri, Tom Foltynie
In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide...
July 5, 2018: Neurodegenerative Disease Management
Noelannah Neubauer, Loretta M Hillier, Cathy Conway, Ron Beleno, Lili Liu
AIM: To describe the proceedings and outcomes of a Locating Technology and Dementia Forum that brought together 109 representatives of researchers, product manufacturers, policy makers, Alzheimer Societies, clinicians, first responders, persons with dementia and care partners. METHODS: Information gathered from this event was used to create strategic direction for advancing the development and use of locating technologies among persons with dementia. RESULTS: Key recommendations from this forum include the need to: fund and conduct research pertaining to usability and effectiveness of technologies; increase awareness about the risk of missing person events; develop a guideline of strategies to manage critical wandering; and engage users in technology development and evaluation...
June 2018: Neurodegenerative Disease Management
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"